Citations

Clear

3042 citation(s) found for "Kumar, S".

DONALD F. RICHARDSON PRIZE PAPERComparing Risk Stratification Criteria for Predicting Lymphatic Dissemination in Endometrial Cancer [06OP]
Kilts, Toni P., Weaver, Amy L. , McGree, Michaela E. , Gostout, Bobbie S., Podratz, Karl C. , Dowdy, Sean C. , Cliby, William A. , Mariani, Andrea , Glaser, Gretchen , Langstraat, Carrie , Kumar, Amanika , Bakkum‐Gamez, Jamie N.

Mayo Clinic

Obstetrics & Gynecology | May 6, 2019 | Volume: 133 | Issue: 1 | Pages: 5-5

10.1097/01.aog.0000559082.68820.f3 Get It

INTRODUCTION: To compare two published risk stratification criteria (Milwaukee Model vs. Mayo Criteria) to predict lymphatic dissemination (LD) in endometrioid endometrial cancer (EC). METHODS: Patients who underwent surgery for EC between 1/1/2004-9/30/2013 and had endometrioid histology without stage IV disease were included and classified as either low-risk or at-risk for LD using two independent risk stratification systems. LD was defined as positive nodes at time of surgery or lymph node recurrence within 2 years of surgery after negative lymph node assessment (LNA) or when LNA was not performed. False positive (FP) and false negative (FN) rates for each risk model were calculated. RESULTS: Among 1103 patients, 81 (7.3%) had LD (72 positive LN and 9 LN recurrences). Most patients (90.2%) had stage I disease. Integration of the Milwaukee Model was associated with a low at-risk rate for LD (38.1%) but a relatively high FN rate (13.6%, 95% CI 7.0-23.0). Conversely, the traditional Mayo Criteria using a tumor diameter (TD) cutoff of ≤2 cm (vs >2 cm) had a higher at-risk rate for LD (69.5%) but a FN rate of 0.0% (95% CI, 0-4.5). Modifying Mayo Criteria using a TD cutoff of ≤3 cm (vs >3 cm) identified fewer women at-risk than using ≤2 cm cutoff (56.8% vs. 69.5%), but had a higher FN rate of 3.7% (95% CI, 0.8-10.4). CONCLUSIONS: The Milwaukee Model had the lowest at-risk rate of LD but an unacceptable FN rate. Modifying the Mayo Criteria by increasing the TD cutoff from the traditional ≤2 cm to ≤3 cm would spare an estimated 12.7% of patients LNA, but the accompanying FN rate is unacceptably high. The traditional Mayo Criteria for low-risk EC remains the most accurate in determining which patients LNA can be omitted.
Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes
Koliani‐Pace, Jenna L., Singh, Siddharth , Luo, Michelle , Hirten, Robert , Kochhar, Gursimran , Chang, Shannon, Lukin, Dana J. , Gao, Youran, Bohm, Matthew , Shmidt, Eugenia , Meserve, Joseph , Winters, Adam C. , Chablaney, Shreya , Yang, Jiao, Huang, Zhongwen, Boland, Brigid S. , Shashi, Preeti , Weiss, Aaron , Varma, Sashidhar, Fischer, Monika , Sultan, Keith , Shen, Bo , Kane, Sunanda V. , Loftus, Edward V. , Sandborn, William J. , Lasch, Karen, Dulai, Parambir S. , Aniwan, Satimai , Loftus, Edward V , Chang, Shannon, Swaminath, Arun C. , Gupta, Nitin Kumar , Faleck, David M. , Weiss, Aaron, Hudesman, David , Sands, Bruce E , Colombel, Jean‐Frédéric , Siegel, Corey A

Mayo Clinic

Inflammatory Bowel Diseases | May 3, 2019 | Volume: 25 | Issue: 11 | Pages: 1854-1861

10.1093/ibd/izz071 | PMID 31050734 Get It

Abstract Background Vedolizumab effectiveness estimates immediately after Food and Drug Administration (FDA) approval for ulcerative colitis (UC) and Crohn’s disease (CD) are limited by use in refractory populations. We aimed to compare treatment patterns and outcomes of vedolizumab in 2 time frames after FDA approval. Methods We used 2 data sets for time trend analysis, an academic multicenter vedolizumab consortium (VICTORY) and the Truven MarketScan database, and 2 time periods, May 2014–June 2015 (Era 1) and July 2015–June 2017 (Era 2). VICTORY cumulative 12-month clinical remission, corticosteroid-free remission, and mucosal healing rates, and Truven 12-month hospitalization and surgery rates, were compared between Eras 1 and 2 using time-to-event analyses. Results A total of 3661 vedolizumab-treated patients were included (n = 1087 VICTORY, n = 2574 Truven). In both cohorts, CD and UC patients treated during Era 2 were more likely to be biologic naïve. Compared with Era 1, Era 2 CD patients in the VICTORY consortium had higher rates of clinical remission (31% vs 40%, P = 0.03) and mucosal healing (42% vs 58%, P < 0.01). These trends were not observed for UC. In the Truven database, UC patients treated during Era 2 had lower rates of inflammatory bowel disease–related hospitalization (22.4% vs 9.6%, P < 0.001) and surgery (17.2% vs 9.4%, P = 0.008), which was not observed for CD. Conclusion Since FDA approval, remission and mucosal healing rates have increased for vedolizumab-treated CD patients, and vedolizumab-treated UC patients have had fewer hospitalizations and surgeries. This is likely due to differences between patient populations treated immediately after drug approval and those treated later.
Assessing the Quality of Abstracts in Randomized Controlled Trials Published in High Impact Cardiovascular Journals
Khan, Muhammad Shahzeb , Ochani, Rohan Kumar , Akhtar, Tauseef , Fatima, Kaneez , Mookadam, Farouk, Murad, M. Hassan , Figueredo, Vincent M. , Murad, M Hassan , Shaikh, Asim , Khan, Safi U. , Mookadam, Farouk , Doukky, Rami , Krasuski, Richard A.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | April 29, 2019 | Volume: 12 | Issue: 5 | Pages: No page available

10.1161/circoutcomes.118.005260 | PMID 31030545 Get It

Background: In the busy world of cardiovascular medicine, abstracts may be the only part of a publication that clinicians read. Therefore, it is critical for abstracts to accurately reflect article content. The extended CONSORT (Consolidated Standards of Reporting Trials) Statement for Abstracts was developed to ensure high abstract quality. However, it is unknown how often adherence to CONSORT guidelines occurs among cardiovascular journals. Methods and Results: We searched MEDLINE for randomized controlled trials published in 3 major cardiovascular journals ( Circulation, Journal of the American College of Cardiology , and European Heart Journal ) from 2011 to 2017. Post hoc, interim, and cost-effective analyses of randomized controlled trials were excluded. Two independent investigators extracted the data using a prespecified data collection form and a third investigator adjudicated the data. The primary outcome was frequency of subcategory adherence to CONSORT guidelines. A total of 478 abstracts were included in the analysis. Approximately half of the abstracts (53%; 255/478; 95% CI, 49%–57%) identified the article as randomized in the title. All abstracts detailed the interventions for both study groups (100%) and 81% (95% CI, 78%–85%) reported trial registration. Methodological quality reporting was relatively low: 9% (45/478; 95% CI, 6%–12%) described participant eligibility criteria with settings for data collection, 43% (204/478; 95% CI, 39%–47%) reported details of blinding, and <1% (4/478; 95% CI, 0%–2%) reported allocation concealment. Approximately 60% (301/478; 95% CI, 59%–67%) of the included abstracts provided primary outcome results while 55% (262/478; 95% CI, 51%–60%) reported harms or adverse effects. Conclusions: There is a high prevalence of nonadherence to CONSORT guidelines among leading cardiovascular journals. Efforts by editors, authors, and reviewers should be made to increase adherence and promote transparent and unbiased presentation of study results.
Evaluation of bone fracture healing in children using acoustic radiation force: Initial in vivo results
Ghavami, Siavash , Gregory, Adriana , Webb, Jeremy, Denis, Max , Milbrandt, Todd A. , Kumar, Viksit , Larson, A. Noelle , Fatemi, Mostafa , Alizad, Azra

Mayo Clinic

The Journal of the Acoustical Society of America | April 24, 2019 | Volume: 145 | Issue: 3_Supplement | Pages: 1893-1893

10.1121/1.5101860 Get It

Vibrational characteristics of the bone are directly dependent on bone’s physical properties. In this paper, a vibrational method for bone evaluation is introduced. We propose a new type of quantitative vibro-acoustic method based on acoustic radiation force of ultrasound for bone characterization in patients with fracture. In this method, we excite the clavicle and ulna by an ultrasound radiation force (URF) pulse. The URF pulse induces vibrations in the bone, resulting in an acoustic wave that is measured by a hydrophone placed on the skin. The resulting acoustic signals were used for wave velocity estimation based on cross-correlation technique. To further separate different vibration characteristics, we adopt a variational mode decomposition (VMD) technique to decompose the received signal into an ensemble of band-limited intrinsic mode functions, which allows analyzing the acoustic signals in terms of their constitutive components. We conducted a prospective study that included a total of 15 patients, 12 with clavicle fractures and 3 with ulna fractures. The contralateral intact bones were used as control. Statistical analysis demonstrated that fracture bones can be differentiated from intact bone with a detection probability of 80%. Also, we introduce a “healing factor” that quantifies the progress of healing in clavicle bones. Statistical analysis showed that healing factor can track the progress of healing in clavicle in 80% of fractures.
Incidence and Risk Factors Associated With 30-Day Readmission for Alcoholic Hepatitis
Garg, Sushil Kumar , Sarvepalli, Shashank , Singh, Dupinder, Obaitan, Itegbemie , Peeraphatdit, Thoetchai , Jophlin, Loretta , Shah, Vijay H. , Leise, Michael D. , Garg, Sushil K, Jophlin, Loretta L , Asrani, Sumeet K.

Mayo Clinic

Journal of Clinical Gastroenterology | April 19, 2019 | Volume: 53 | Issue: 10 | Pages: 759-764

10.1097/mcg.0000000000001202 | PMID 30950924 Get It

Background: Alcohol abuse and liver disease are associated with high rates of 30-day hospital readmission, but factors linking alcoholic hepatitis (AH) to readmission are not well understood. We aimed to determine the incidence rate of 30-day readmission for patients with AH and to evaluate potential predictors of readmission. Methods: We used the Nationwide Readmissions Database to determine the 30-day readmission rate for recurrent AH between 2010 and 2014 and examined trends in readmissions during the study period. We also identified the 20 most frequent reasons for readmission. Multivariate survey logistic regression analysis was used to identify factors associated with 30-day readmission. Results: Of the 61,750 index admissions for AH, 23.9% were readmitted within 30-days. The rate of readmission did not change significantly during the study period. AH, alcoholic cirrhosis, and hepatic encephalopathy were the most frequent reasons for readmission. In multivariate analysis female sex, leaving against medical advice, higher Charlson comorbidity index, ascites, and history of bariatric surgery were associated with earlier readmissions, whereas older age, payer type (private or self-pay/other), and discharge to skilled nursing-facility reduced this risk. Conclusions: The 30-day readmission rate in patients with AH was high and stable during the study period. Factors associated with readmission may be helpful for development of consensus-based expert guidelines, treatment algorithms, and policy changes to help decrease readmission in AH.
Higher CD3 cell counts in apheresis collection in relation to superior survival in patients with multiple myeloma.
Kim, Sharon , Lacy, Martha Q. , Hayman, Suzanne R. , Kapoor, Prashant , Gastineau, Dennis A., Porrata, Luis F. , Kumar, Shaji , Gertz, Morie A. , Dispenzieri, Angela , Buadi, Francis K. , Dingli, David , Winters, Jeffrey L. , Gastineau, Dennis A. , Hogan, William J.

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 11085-11085

10.1200/jco.2015.33.15_suppl.11085 Get It

Second primary malignancies in hepatocellular carcinoma: A population-based study.
Shah, Binay Kumar , Kandel, Pujan , Khanal, Amit

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 9563-9563

10.1200/jco.2015.33.15_suppl.9563 Get It

Outcomes and treatment of patients with POEMS syndrome experiencing progression or relapse after first line treatment.
Kourelis, Taxiarchis , Kyle, Robert A. , Kumar, Shaji , Lacy, Martha Q. , Kapoor, Prashant , Lust, John A., Hayman, Suzanne R. , Zeldenrust, Steven R., Gertz, Morie A. , Buadi, Francis K. , Go, Ronald S. , Rajkumar, S. Vincent , Dingli, David , Lin, Yi , Leung, Nelson , Dispenzieri, Angela

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 8594-8594

10.1200/jco.2015.33.15_suppl.8594 Get It

Patterns of AKT, mTOR, ERK, and STAT3 pathway activation in MGUS, smoldering multiple myeloma, and multiple myeloma.
Larsen, Jeremy T. , Wellik, Linda, Kimlinger, Teresa K. , Kumar, Shaji , Ramakrishnan, Vijay , Rajkumar, S. Vincent

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 8589-8589

10.1200/jco.2015.33.15_suppl.8589 Get It